Treatment modalities of newly diagnosed AML (ND AML) depend on age, fitness, and molecular risk groups based on cytogenetics and the presence of molecular alterations, such as fms like tyrosine kinase 3 (FLT3), nucleophosmin 1 (NPM1), or tumor protein p53 (TP53) mutations, as defined in the ELN 2017 classification [1]. Here, NPM1 is linked to acute myeloid leukemia.